サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1301062

ハンチントン病治療の市場規模、シェア、動向分析レポート：治療法別、最終用途別、地域別、セグメント予測、2023年～2030年

Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
ハンチントン病治療の市場規模、シェア、動向分析レポート：治療法別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年06月19日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ハンチントン病治療市場の成長と動向

GrandView Research, Inc.の最新レポートによると、世界のハンチントン病治療市場規模は2030年までに18億7,120万米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 23.20％で拡大すると予測されています。この成長は、新製品開発のための高い研究開発投資、研究協力、欧米諸国における高HD負担によるものです。ハンチントン病は、数世代にわたって罹患するまれな遺伝性神経変性疾患です。30歳から50歳の間に発症し、仕事や家族の世話をする能力が損なわれ、最終的には日常の仕事をこなすことができなくなります。

有病率は地域によって10倍以上の差があり、これは症例の把握や診断基準のばらつきに関係していると考えられます。有病率は地理的な場所によって10倍以上の差があり、これは症例確認や診断基準のばらつきに関係している可能性があります。その結果、一般集団における反復性肥大の有病率は予想以上に高い可能性があります。アジアでは一貫して有病率が低く、北米、オーストラリアでは有病率が高いです。

Neurocrine Biosciences, Inc.やAzevan Pharmaceuticals, Inc.などの主な企業は、HDの対症療法の研究開発に注力しています。Azevan Pharmaceuticals社は、ハンチントン病の精神神経症状を治療する実験薬としてSRX246を開発しています。SRX246は、脳内のバソプレシン1a（V1a）受容体を阻害することで効果を発揮する薬剤です。神経系では、V1a受容体は主要なバソプレシン受容体です。SRX246は、V1a受容体を阻害することにより、バソプレシンが受容体に結合するのを制限し、ハンチントン病患者に見られる過敏で攻撃的な行動を引き起こします。

しかし、現在承認されている薬剤は対症療法や緩和ケアであり、病気の根本的な原因を治療するものではないです。薬物療法は症状の重篤度を減少させることはできるが、傾眠、歩行障害、嚥下障害、無気力などの副作用を伴うことが多く、患者のQOLに深刻な影響を与えます。この疾患の治療法が確立されていないことを考えると、これらの患者において健康関連QOL（HRQOL）がどのような影響を受けるかを評価することは極めて重要です。病気の初期から中期のHD患者には、認知機能の評価やカウンセリングなど、集学的な医療サービスが必要です。

HDに対する薬剤開発は、いくつかの治療法が有効性を実証できなかったり、重大な毒性を伴うなど、大きな障害に直面してきました。2020年9月、Vaccinex Inc.のペピネマブの第II相試験は、初期の顕性HD患者および前駆期HD患者を対象として、事前に指定された共同主要評価項目を満たすことができなかっています。SIGNAL試験において、2つの共同主要評価項目（ハンチントン病認知機能評価バッテリーとCGIC（Clinical Global Impression of Change）の2つの認知機能評価項目）は、早期症状集団において統計学的有意性を達成しなかっています。

ハンチントン病治療市場レポートハイライト

  • 対症療法分野は、製品の入手可能性と特許保護により、2022年に最大の売上シェアを占めました。疾患修飾療法は、SAGE-718およびCellavita-HDの参入により、予測期間中に最も急成長する分野と予想されます。
  • 各社は現在、変異タンパク質を標的とするのではなく、脳に直接注射して変異HTTタンパク質の形成を直接阻害する治療法の開発に注力しています。
  • 開発初期段階にある新規ターゲットの薬剤には、Cellavita社とAzidus Brazil社のCellavita HD（幹細胞治療）、Sangamo Therapeutics社のmHTT ZFP（ジンクフィンガータンパク質）、UniQure社のAMT-130（遺伝子治療）などがあります。
  • 北米は2022年に最も高い収益シェアを占め、償還制度が充実していること、米国とカナダではHDの負担が大きいことから、予測期間中も市場を独占するとみられます。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
  • 地域の範囲
  • 推定・予測のタイムライン
  • 目的
  • 調査手法
  • 情報調達
  • 情報またはデータ分析
  • 市場の形成と検証
  • モデル詳細
  • 二次情報のリスト
  • 略語のリスト

第2章 エグゼクティブサマリー

  • 市場スナップショット
  • セグメントのスナップショット
  • 競合情勢のスナップショット

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/アンシラリー市場見通し
  • 市場動向と展望
  • 市場力学
    • 市場抑制要因分析
    • 市場抑制要因分析
  • 事業環境分析
    • SWOT分析;要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析

第4章 製品ビジネス分析

  • ハンチントン病治療市場：治療変動分析
  • 対症療法
  • 疾患修飾療法

第5章 エンドユーザービジネス分析

  • ハンチントン病治療市場：エンドユーザーの変動分析
    • 病院薬局
    • 小売薬局
    • eコマース

第6章 地域ビジネス分析

  • 地域別ハンチントン病治療市場シェア、2022年および2030年
  • 北米
    • SWOT分析
    • 北米ハンチントン病治療市場、2018年～2030年
    • 米国
    • カナダ
  • 欧州
    • SWOT分析
    • 欧州ハンチントン病治療市場、2018年～2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • SWOT分析
    • アジア太平洋地域のハンチントン病治療市場、2018年～2030年
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • SWOT分析
    • ラテンアメリカのハンチントン病治療市場、2018年～2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • MEA
    • SWOT分析
    • MEAハンチントン病治療市場、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 会社の分類
  • 戦略マッピング
  • 主要企業の市場シェア分析、2022年
  • 企業プロファイル
    • H. LUNDBECK A/S
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • BAUSCH HEALTH COMPANIES INC.
    • HETERO
    • LUPIN
    • HIKMA PHARMACEUTICALS PLC
    • DR. REDDY'S LABORATORIES LTD.
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Huntington's Disease Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 5 Global Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 6 Global Huntington's Disease Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 9 North America Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 11 U.S. Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 12 Canada Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 13 Canada Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 14 Europe Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 16 Europe Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 17 Germany Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 18 Germany Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 19 UK Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 20 UK Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 21 France Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 22 France Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 23 Italy Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 24 Italy Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 25 Spain Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 26 Spain Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 27 Denmark Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 28 Denmark Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 29 Sweden Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 30 Sweden Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 31 Norway Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 32 Norway Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 36 China Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 37 China Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 38 Japan Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 39 Japan Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 40 India Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 41 India Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 42 South Korea Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 43 South Korea Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 44 Australia Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 45 Australia Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 46 Thailand Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 47 Thailand Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 48 Latin America Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Latin America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 50 Latin America Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 51 Brazil Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 52 Brazil Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 53 Mexico Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 54 Mexico Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 55 Argentina Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 56 Argentina Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 60 South Africa Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 61 South Africa Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 63 Saudi Arabia Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 64 UAE Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 65 UAE Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain - Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Huntington's Disease Treatment Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Huntington's Disease Treatment Market: by Treatment Movement Analysis
  • Fig. 15 Global Huntington's Disease Treatment Market, for Symptomatic treatment, 2018 - 2030 (USD Million)
  • Fig. 16 Global Huntington's Disease Treatment Market, for Disease - modifying therapies, 2018 - 2030 (USD Million)
  • Fig. 17 Global Huntington's Disease Treatment Market: End use Movement Analysis
  • Fig. 18 Global Huntington's Disease Treatment Market, for Pharmaceutical & Biotechnology Companies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Huntington's Disease Treatment Market, for Hospital pharmacy, 2018 - 2030 (USD Million)
  • Fig. 20 Global Huntington's Disease Treatment Market, for Retail pharmacy, 2018 - 2030 (USD Million)
  • Fig. 21 Global Huntington's Disease Treatment Market, for E - commerce, 2018 - 2030 (USD Million)
  • Fig. 22 Regional Marketplace: Key Takeaways Huntington's Disease Treatment Market, Region 2018 - 2030 (USD Million)
  • Fig. 23 Huntington's Disease Treatment Market :Regional Outlook, 2022 & 2030 2018 - 2030 (USD Million)
  • Fig. 24 North America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 26 Canada Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 27 Europe Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 29 UK Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 30 France Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 31 Italy Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 32 Spain Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 33 Denmark Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 34 Sweden Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 35 Norway Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 37 Japan Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 38 China Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 39 India Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 40 Australia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 42 Thailand Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 48 South Africa Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 49 Saudi Arabia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 50 UAE Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-552-6

Huntington's Disease Treatment Market Growth & Trends

The global Huntington's disease treatment market size is expected to reach USD 1,871.2 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 23.20% from 2023 to 2030. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.

The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.

The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.

However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient's quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.

Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.

Huntington's Disease Treatment Market Report Highlights

  • The symptomatic treatment segment accounted for the largest revenue share in 2022 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
  • Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
  • Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy)
  • North America held the highest revenue share in 2022 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Treatment Segment
      • 1.1.1.2 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends And Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Market Restraint Analysis
      • 3.4.1.1. Strong Product Pipeline
      • 3.4.1.2. Disease Burden Of Huntington's In Developed Countries
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. Significant Challenges And Unmet Needs In Huntington's Disease Treatment
      • 3.4.2.2. High Failure Rate In Clinical Trials
  • 3.5. Business Environment Analysis
    • 3.5.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Product Business Analysis

  • 4.1 Huntington's Disease Treatment Market: Treatment Movement Analysis
  • 4.2 Symptomatic Treatment
    • 4.2.1 Symptomatic Treatment Market, 2018 - 2030 (USD Million)
  • 4.3 Disease-Modifying Therapies
    • 4.3.1 Disease-Modifying Therapies Market, 2018 - 2030 (USD Million)

Chapter 5. End User Business Analysis

  • 5.1 Huntington's Disease Treatment Market: End User Movement Analysis
    • 5.1.1 Hospital Pharmacy
      • 5.1.1.1 Hospital Pharmacy market estimates and forecast, 2018 - 2030
    • 5.1.2 Retail Pharmacy
      • 5.1.2.1 Retail Pharmacy market estimates and forecast, 2018 - 2030
    • 5.1.3 E-Commerce
      • 5.1.3.1 E-Commerce market estimates and forecast, 2018 - 2030

Chapter 6. Regional Business Analysis

  • 6.1. Huntington's Disease Treatment Market Share By Region, 2022 & 2030
  • 6.2. North America
    • 6.2.1. SWOT Analysis
    • 6.2.2. North America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. Reimbursement Scenario
      • 6.2.3.6. U.S. Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Competitive Scenario
      • 6.2.4.4. Regulatory Framework
      • 6.2.4.5. Reimbursement Scenario
      • 6.2.4.6. Canada Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Swot Analysis
    • 6.3.2. Europe Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. Reimbursement Scenario
      • 6.3.3.6. Germany Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.4. UK
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. Reimbursement Scenario
      • 6.3.4.6. UK Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. Reimbursement Scenario
      • 6.3.5.6. France Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Reimbursement Scenario
      • 6.3.6.6. Italy Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Regulatory Framework
      • 6.3.7.5. Reimbursement Scenario
      • 6.3.7.6. Spain Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Regulatory Framework
      • 6.3.8.5. Reimbursement Scenario
      • 6.3.8.6. Denmark Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Regulatory Framework
      • 6.3.9.5. Reimbursement Scenario
      • 6.3.9.6. Sweden Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1. Key Country Dynamics
      • 6.3.10.2. Target Disease Prevalence
      • 6.3.10.3. Competitive Scenario
      • 6.3.10.4. Regulatory Framework
      • 6.3.10.5. Reimbursement Scenario
      • 6.3.10.6. Norway Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Swot Analysis
    • 6.4.2. Asia Pacific Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. Reimbursement Scenario
      • 6.4.3.6. Japan Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. Reimbursement Scenario
      • 6.4.4.6. China Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Regulatory Framework
      • 6.4.5.5. Reimbursement Scenario
      • 6.4.5.6. India Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Regulatory Framework
      • 6.4.6.5. Reimbursement Scenario
      • 6.4.6.6. South Korea Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.7. Australia
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Regulatory Framework
      • 6.4.7.5. Reimbursement Scenario
      • 6.4.7.6. Australia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.8. Thailand
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Competitive Scenario
      • 6.4.8.4. Regulatory Framework
      • 6.4.8.5. Reimbursement Scenario
      • 6.4.8.6. Thailand Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. SWOT Analysis
    • 6.5.2. Latin America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Regulatory Framework
      • 6.5.3.5. Reimbursement Scenario
      • 6.5.3.6. Brazil Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Regulatory Framework
      • 6.5.4.5. Reimbursement Scenario
      • 6.5.4.6. Mexico Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Regulatory Framework
      • 6.5.5.5. Reimbursement Scenario
      • 6.5.5.6. Argentina Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. SWOT Analysis
    • 6.6.2. MEA Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Regulatory Framework
      • 6.6.3.5. Reimbursement Scenario
      • 6.6.3.6. South Africa Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Regulatory Framework
      • 6.6.4.5. Reimbursement Scenario
      • 6.6.4.6. Saudi Arabia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Regulatory Framework
      • 6.6.5.5. Reimbursement Scenario
      • 6.6.5.6. UAE Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Regulatory Framework
      • 6.6.6.5. Reimbursement Scenario
      • 6.6.6.6. Kuwait Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1 Company Categorization
  • 7.2 Strategy Mapping
    • 7.1.1. New Product Launch
    • 7.1.2. Partnerships
    • 7.1.3. Acquisition
    • 7.1.4. Collaboration
    • 7.1.5. Funding
  • 7.3 Key Company Market Share Analysis, 2022
  • 7.4 Company Profiles
    • 7.4.1 H. LUNDBECK A/S
      • 7.4.1.1 Company overview
      • 7.4.1.2 Financial performance
      • 7.4.1.3 Product benchmarking
      • 7.4.1.4 Strategic Initiatives
    • 7.4.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 7.4.2.1 Company overview
      • 7.4.2.2 Financial performance
      • 7.4.2.3 Product benchmarking
      • 7.4.2.4 Strategic Initiatives
    • 7.4.3 BAUSCH HEALTH COMPANIES INC.
      • 7.4.3.1 Company overview
      • 7.4.3.2 Financial performance
      • 7.4.3.3 Product benchmarking
      • 7.4.3.4 Strategic Initiatives
    • 7.4.4 HETERO
      • 7.4.4.1 Company overview
      • 7.4.4.2 Product benchmarking
      • 7.4.4.3 Strategic Initiatives
    • 7.4.5 LUPIN
      • 7.4.5.1 Company overview
      • 7.4.5.2 Financial performance
      • 7.4.5.3 Product benchmarking
      • 7.4.5.4 Strategic Initiatives
    • 7.4.6 HIKMA PHARMACEUTICALS PLC
      • 7.4.6.1 Company overview
      • 7.4.6.2 Financial performance
      • 7.4.6.3 Product benchmarking
      • 7.4.6.4 Strategic Initiatives
    • 7.4.7 DR. REDDY'S LABORATORIES LTD.
      • 7.4.7.1 Company overview
      • 7.4.7.2 Financial performance
      • 7.4.7.3 Product benchmarking
      • 7.4.7.4 Strategic Initiatives
    • 7.4.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 7.4.8.1 Company overview
      • 7.4.8.2 Financial performance
      • 7.4.8.3 Product benchmarking
      • 7.4.8.4 Strategic Initiatives